(682) 651-1112
(682) 651-1112
Our research expertise spans the conditions and biological pathways that define liver and metabolic health.
Evidentis is a specialty clinical trials center conducting research across liver disease, metabolic and obesity-related disorders, cardiometabolic health, immune-mediated inflammation, and early-phase pharmacokinetic (PK) investigation. These areas reflect the core therapeutic domains where meaningful advances in patient outcomes are most needed.
Each focus area is supported by subspecialty clinical insight, precise operational workflows, and high-quality data processes. Explore the sections below to learn more about the types of conditions and research focus within each domain.
Evidentis conducts clinical trials across the full spectrum of liver disease, from metabolic dysfunction and alcohol-related injury to autoimmune and cholestatic disorders, including advanced fibrosis and cirrhosis.
Evidentis conducts clinical research focused on obesity, insulin resistance, dyslipidemia, and broader metabolic dysfunction. Studies in this area evaluate investigational therapies targeting weight regulation, glucose metabolism, lipid pathways, and other mechanisms central to metabolic and cardiometabolic health.
Evidentis conducts clinical research at the intersection of metabolic disease and cardiovascular function. Studies in this area evaluate investigational therapies that may influence blood pressure regulation, vascular function, lipid pathways, and other contributors to long-term cardiometabolic risk.
Evidentis conducts clinical research focused on immune-mediated conditions and inflammatory pathways that influence liver and metabolic disease. Studies in this area evaluate investigational therapies designed to modulate immune activity, target inflammatory mechanisms, and address immune-driven disease processes relevant to chronic liver and metabolic disorders.
Evidentis conducts early phase clinical research designed to understand how investigational therapies behave in the body. Studies in this area evaluate pharmacokinetics (PK), safety, tolerability, and dose-related characteristics that inform later-stage development. Our dedicated research suite supports controlled environments, precise workflow execution, and intensive sampling protocols.